Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: A pilot study

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 5, 2013, Pages 1083-1092

  Jiang, Lan ^a,c   Weatherall, Paul T ^a   McColl, Roderick W ^a   Tripathy, Debu ^b   Mason, Ralph P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Department of Radiation Oncology ^*  (United States)

Author keywords

BOLD MRI; breast cancer; neoadjuvant chemotherapy; oxygen; prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; ARTICLE; BOLD SIGNAL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SIZE; CLINICAL ARTICLE; FEMALE; HUMAN; IMAGE QUALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OXYGEN BREATHING; PILOT STUDY; PRIORITY JOURNAL; PULSE RATE; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONTRAST MEDIA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OXYGEN; PACLITAXEL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84876497189     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23891     Document Type: Article

References (47)

1. Gray L, Conger A, Ebert M, Hornsey S, Scott O,. The concentration of oxygen dissolved in tissues at time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-648.
2. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82: 699-757.
3. Fyles A, Milosevic M, Pintilie M, et al. Long-term performance of interstitial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol 2006; 80: 132-137.
4. Brizel DM, Sibly GS, Prosmitz LR, Scher RL, Dewhirst MW,. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
5. Kaanders JHAM, Wijffels KIEM, Marres HAM, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002; 62: 7066-7074.
6. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12: 1507-1514.
7. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002; 60: 634-639.
8. 2 tension measurements. Cancer Res 1991; 51: 3316-3322.
9. Runkel S, Kaven E,. In vivo distribution of oxygen partial pressures in female breast tumors. In:, Vaupel P, Kelleher D,. eds, Tumor hypoxia: pathophysiology, clinical significance and therapeutic perspectives. Stuttgart, Germany: Wissenschaftliche verlagsgesellschaft mbh; 1999. p 13-18.
10. Hohenberger P, Felgner C, Haensch W, Schlag PM,. Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res Treat 1998; 48: 97-106.
11. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10: 260-266.
12. Le-Petross HC, Hylton N,. Role of breast MR imaging in neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am 2010; 18: 249-258.
13. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. Am J Roentgenol 2005; 184: 1774-1781.
14. Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011; 29: 660-666.
15. Li SP, Makris A, Beresford MJ, et al. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology 2011; 260: 68-78.
16. Robinson SP, Howe FA, Rodrigues LM, Stubbs M, Griffiths JR,. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin Radiat Oncol 1998; 8: 198-207.
17. Al-Hallaq HA, River JN, Zamora M, Oikawa H, Karczmar GS,. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. Int J Radiat Oncol Biol Phys 1998; 41: 151-159.
18. 2) inside tumors? Magn Reson Med 2002; 48: 980-986.
19. Elas M, Williams BB, Parasca A, et al. Quantitative tumor oxymetric images from 4D electron paramagnetic resonance imaging (EPRI): methodology and comparison with blood oxygen level-dependent (BOLD) MRI. Magn Reson Med 2003; 49: 682-691.
20. 19F MRI to investigate tumor oxygenation. Magn Reson Med 2009; 62: 357-364.
21. McPhail LD, Robinson SP,. Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis. Radiology 2010; 254: 110-118.
22. Taylor NJ, Baddeley H, Goodchild KA, et al. BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 2001; 14: 156-163.
23. Fischer DR, Reichenbach JR, Rauscher A, Sedlacik J, Kaiser WA,. Application of an exogenous hyperoxic contrast agent in MR mammography: initial results. Eur Radiol 2005; 15: 829-832.
24. Rakow-Penner R, Daniel B, Glover GH,. Detecting blood oxygen level-dependent (BOLD) contrast in the breast. J Magn Reson Imaging 2010; 32: 120-129.
25. Therasse P, Arbuck SG, Eisenhaue EA,. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000; 92: 205-216.
26. Liu SV, Melstrom L, Yao K, Russell CA, Sener SF,. Neoadjuvant therapy for breast cancer. J Surg Oncol 2010; 101: 283-291.
27. Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006; 239: 361-374.
28. Wasser, Klein, Fink, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 2003; 13: 80-87.
29. Baddeley H, Brodrick PM, Taylor NJ, et al. Gas exchange parameters in radiotherapy patients during breathing of 2%, 3.5% and 5% carbogen gas mixtures. Br J Radiol 2000; 73: 1100-1104.
30. Prisman E, Slessarev M, Azami T, Nayot D, Milosevic M, Fisher J,. Modified oxygen mask to induce target levels of hyperoxia and hypercarbia during radiotherapy: a more effective alternative to carbogen. Int J Radiat Biol 2007; 83: 457-462.
31. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ,. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97-100.
32. Griffiths JR, Taylor NJ, Howe FA, et al. The response of human tumors to carbogen breathing monitored by gradient-recalled echo MRI. Int J Radiat Oncol Biol Phys 1997; 39: 697-701.
33. Howe FA, Robinson SP, McIntyre DJO, Stubbs M, Griffiths JR,. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001; 14: 497-506.
34. Li SP, Taylor NJ, Makris A, et al. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology 2010; 257: 643-652.
35. Hoskin PJ, Carnell DM, Taylor NJ, et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 2007; 68: 1065-1071.
36. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A,. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2002; 53: 1185-1191.
37. Boss A, Martirosian P, Jehs MC, et al. Influence of oxygen and carbogen breathing on renal oxygenation measured by T2-weighted imaging at 3.0 T. NMR Biomed 2009; 22: 638-645.
38. Li SP, Padhani AR, Taylor NJ, et al. Imaging tumor hypoxia with BOLD MRI in primary breast cancer. J Clin Oncol 2010; 28: e13526.
39. Silvennoinen MJ, Clingman CS, Golay X, Kauppinen RA, van Zijl PC,. Comparison of the dependence of blood R2 and R2* on oxygen saturation at 1.5 and 4.7 Tesla. Magn Reson Med 2003; 49: 47-60.
40. Fan B, Wang X-y, Yang X-d, Zhong H, Wu C-x, Jiang X-x,. Blood oxygen level-dependent MRI for the monitoring of neoadjuvant chemotherapy in breast carcinoma: initial experience. Magn Reson Imaging 2011; 29: 153-159.
41. O'Connor JPB, Naish JH, Parker GJM, et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009; 75: 1209-1215.
42. Chen JH, Feig BA, Hsiang DJB, et al. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg 2009; 249: 448-454.
43. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM,. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with X-ray mammography and palpation. J Magn Reson Imaging 2001; 13: 868-875.
44. Tozaki M, Sakamoto M, Oyama Y, et al. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with H-1 MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 2008; 28: 420-427.
45. 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011; 38: 426-435.
46. Jiang SD, Pogue BW, Carpenter CM, et al. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology 2009; 252: 551-560.
47. Padhani AR, Miles KA,. Multiparametric imaging of tumor response to therapy. Radiology 2010; 256: 348-364.